What is Innovative Medtech Inc's earnings per share (EPS)?

Innovative Medtech Inc (IMTH) reported diluted earnings per share of $0.03 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Innovative Medtech Inc Financials

IMTH

FY2025 annual

Revenue Not reported for FY2025

Net Income Not reported for FY2025

EPS (Diluted) $0.03 YoY not available

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2025 Currency USD FYE June

This page shows Innovative Medtech Inc (IMTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IMTH FY2025 2026-08-15

AnTix looks less like a scaling operator and more like a cash-constrained balance-sheet workout funded by share issuance.

Across FY2023-FY2024, reported losses stayed in the multi-million range, but operating cash outflow stayed near $169K-$183K, so accounting losses and cash consumption were telling very different stories. That gap matters because FY2025 ended with only $14K of cash and a current ratio of 0.02x, making near-term liquidity tighter than the headline losses alone suggest.

The FY2025 balance sheet is dominated by short-term obligations: total liabilities and current liabilities were both about $1.3M, while total assets were only about $250K. That structure means the issue is not long-dated leverage; it is whether the business can keep enough liquidity in place to meet bills coming due soon.

From FY2023 to FY2024, revenue hovered around $1.7M-$1.8M while operating losses remained above twice sales, which suggests the cost base did not shrink in step with a small revenue footprint. Meanwhile, shares outstanding jumped from 23.9M to 53.7M by FY2025, pointing to equity financing as a key support even though it did not rebuild a cash cushion.

Financial Health Signals

Financial health score not available

Innovative Medtech Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

EPS (Diluted)

$0.03

Innovative Medtech Inc earned $0.03 per diluted share (EPS) in fiscal year 2025.

Revenue

Not reported for fiscal year 2025.

EBITDA

Not reported for fiscal year 2025.

Net Income

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$14K

YoY+1459.7%

5Y CAGR+77.8%

10Y CAGR-2.0%

Innovative Medtech Inc held $14K in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

54M

Innovative Medtech Inc had 54M shares outstanding in fiscal year 2025.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

None of these metrics is reported for fiscal year 2025.

Capital Allocation

None of these metrics is reported for fiscal year 2025.

IMTH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

IMTH annual income statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY14	FY13	FY12	FY11	FY10
Revenue	N/A	$1.8M+5.8%	$1.7M+32.9%	$1.3M+271.7%	$349K	$0	$0	$0	$0-100.0%	$668K-12.3%	$762K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0	$0-100.0%	$558K
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0	$0-100.0%	$87K
SG&A Expenses	$360K+1364.6%	$25K-97.5%	$973K+4.2%	$933K+215.9%	$295K	N/A	N/A	$86K-85.3%	$586K+205.0%	$192K-61.0%	$492K
Operating Income	N/A	-$4.0M-10.5%	-$3.6M+80.1%	-$18.3M-2475.6%	-$709K	N/A	N/A	-$284K+80.0%	-$1.4M	N/A	N/A
Interest Expense	$85K-2.9%	$87K-43.6%	$155K-15.1%	$183K+5.9%	$172K	N/A	N/A	$232K+176.6%	$84K-8.6%	$92K+222.0%	-$75K
Income Tax	$0	$0	N/A	N/A	N/A	N/A	$0	$0	$0	$0	N/A
Net Income	N/A	-$7.9M-117.6%	-$3.6M+79.8%	-$18.1M-453.1%	-$3.3M	N/A	N/A	-$567K+61.9%	-$1.5M-35.1%	-$1.1M+45.3%	-$2.0M
EPS (Diluted)	$0.03	-$0.33	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	$428K-6.1%	$456K+0.3%	$455K+5.2%	$433K-10.0%	$481K
SG&A Expenses	N/A	N/A	$17K-84.9%	$115K+127.1%	-$426K-294.7%	$219K+3902.8%	$5K-97.6%	$226K
Operating Income	N/A	-$57K+94.7%	-$1.1M-29.9%	-$827K+71.5%	-$2.9M-234.9%	-$865K-822.0%	-$94K+36.1%	-$147K
Interest Expense	N/A	$42K+41.9%	$30K+1.2%	$30K+20.4%	$25K-19.9%	$31K+196.5%	$10K-52.7%	$22K
Income Tax	N/A	$0	$0	N/A	N/A	$0	$0	N/A
Net Income	N/A	-$89K+92.1%	-$1.1M-27.3%	-$884K	N/A	-$910K-383.6%	-$188K-14.0%	-$165K
EPS (Diluted)	N/A	$0.00	-$0.04	N/A	N/A	-$0.04-300.0%	-$0.01	N/A

Not reported in any period shown, so not listed: R&D Expenses.

No annual filing on record for: FY2015, FY2016, FY2017, FY2018, FY2019.

IMTH Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

IMTH annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY14	FY13	FY12	FY11	FY10
Total Assets	$250K-61.6%	$652K-85.3%	$4.4M-7.3%	$4.8M-6.5%	$5.1M+669925.7%	$766	$608	$0	$0-100.0%	$86K-52.6%	$181K
Current Assets	$23K-91.9%	$284K-27.9%	$394K-23.5%	$515K-22.3%	$663K+86417.2%	$766	N/A	N/A	$0-100.0%	$83K-51.2%	$171K
Cash & Equivalents	$14K+1459.7%	$873-22.1%	$1K-99.6%	$301K-30.5%	$433K+56484.2%	$766	$608	$0	$0	$0-100.0%	$17K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$7K-78.0%	$34K
Accounts Receivable	$0-100.0%	$161K-28.3%	$225K+20.6%	$186K+4.3%	$179K	$0	N/A	N/A	$0-100.0%	$76K-37.0%	$121K
Goodwill	N/A	$0-100.0%	$178K0.0%	$178K-94.7%	$3.4M	$0	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.3M-78.8%	$6.1M+6.5%	$5.8M-7.3%	$6.2M+19.7%	$5.2M+28.4%	$4.0M	$3.0M+13.7%	$2.7M+27.0%	$2.1M-21.0%	$2.7M-24.7%	$3.5M
Current Liabilities	$1.3M-68.2%	$4.1M+14.7%	$3.6M-7.2%	$3.9M+38.0%	$2.8M-30.9%	$4.0M	$3.0M+13.7%	$2.7M+27.0%	$2.1M-21.0%	$2.7M-4.1%	$2.8M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$14K-92.8%	$201K	N/A	N/A	N/A	N/A	$131K
Total Equity	-$1.1M+80.8%	-$5.5M-319.1%	-$1.3M+7.2%	-$1.4M-2443.9%	-$55K+98.6%	-$4.0M	-$3.0M-13.7%	-$2.7M-27.0%	-$2.1M+18.3%	-$2.6M+23.2%	-$3.3M
Retained Earnings	-$43.3M+2.8%	-$44.6M-21.7%	-$36.6M-11.1%	-$33.0M-121.1%	-$14.9M-28.0%	-$11.7M	-$10.3M-3.7%	-$9.9M-6.1%	-$9.3M-19.0%	-$7.8M-18.5%	-$6.6M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$250K-76.4%	$1.1M-6.1%	$1.1M-11.5%	$1.3M+96.2%	$652K-86.0%	$4.7M+7.6%	$4.3M-5.3%	$4.6M
Current Assets	$23K-90.9%	$250K-5.8%	$266K-26.0%	$359K+26.6%	$284K-58.7%	$688K+130.4%	$298K-39.4%	$492K
Cash & Equivalents	$14K+3779.2%	$351+258.2%	$98-99.9%	$174K+19864.8%	$873+42.4%	$613+6.1%	$578-99.8%	$257K
Accounts Receivable	$0	N/A	N/A	$166K+3.4%	$161K-27.0%	$221K+12.7%	$196K-12.9%	$225K
Goodwill	N/A	N/A	N/A	N/A	$0-100.0%	$178K0.0%	$178K0.0%	$178K
Total Liabilities	$1.3M-78.1%	$6.0M-0.4%	$6.0M-5.2%	$6.3M+2.8%	$6.1M+1.6%	$6.0M+1.1%	$6.0M-0.9%	$6.0M
Current Liabilities	$1.3M-67.5%	$4.0M+0.6%	$4.0M-6.5%	$4.3M+4.1%	$4.1M+3.9%	$3.9M+3.8%	$3.8M-0.6%	$3.8M
Total Equity	-$1.1M+78.5%	-$4.9M-1.0%	-$4.8M+3.6%	-$5.0M+8.3%	-$5.5M-298.3%	-$1.4M+16.0%	-$1.6M-13.0%	-$1.5M
Retained Earnings	-$43.3M+7.2%	-$46.7M-0.2%	-$46.6M-2.5%	-$45.4M-2.0%	-$44.6M-17.6%	-$37.9M-2.5%	-$37.0M-0.5%	-$36.8M

No annual filing on record for: FY2015, FY2016, FY2017, FY2018, FY2019.

IMTH Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

IMTH annual cash flow statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY14	FY13	FY12	FY11	FY10
Operating Cash Flow	N/A	-$183K-8.4%	-$169K+71.0%	-$583K-2174.3%	$28K	N/A	N/A	$0+100.0%	-$53K+21.4%	-$68K+88.2%	-$578K
Capital Expenditures	N/A	$51K+302.4%	$13K-72.8%	$46K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	-$234K-28.8%	-$182K+71.1%	-$629K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	-$51K-1037.9%	$5K+153.0%	-$10K+99.3%	-$1.6M	$0	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	$190K+857.1%	$20K-95.7%	$461K-76.6%	$2.0M	N/A	N/A	$0-100.0%	$53K+4.2%	$51K-91.4%	$594K

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	N/A	-$18K+83.3%	-$106K-444.5%	$31K-40.4%	$52K+409.6%	-$17K+90.9%	-$183K-420.1%	-$35K
Capital Expenditures	N/A	N/A	N/A	$12K-74.1%	-$45K	$0	$0-100.0%	$95K
Free Cash Flow	N/A	N/A	N/A	$19K+166.3%	$7K+143.3%	-$17K+90.9%	-$183K-40.3%	-$130K
Investing Cash Flow	N/A	N/A	N/A	-$12K-125.9%	$45K	$0	$0+100.0%	-$95K
Financing Cash Flow	N/A	N/A	$77K+86.5%	$41K+5694.7%	$716-98.2%	$39K+149.0%	-$79K-134.6%	$229K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

No annual filing on record for: FY2015, FY2016, FY2017, FY2018, FY2019.

IMTH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

IMTH annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY14	FY13	FY12	FY11	FY10
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.0%-11.4pp	11.4%
Operating Margin	N/A	-219.4%	-210.1%	-1407.0%	-203.0%	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	-435.0%	-211.5%	-1391.7%	-935.1%	N/A	N/A	N/A	N/A	-164.8%	-264.3%
Return on Assets	N/A	-1217.8%-1135.9pp	-82.0%+294.2pp	-376.2%-312.6pp	-63.6%	N/A	N/A	N/A	N/A	-1280.3%-169.7pp	-1110.6%
Current Ratio	0.02-0.1x	0.070.0x	0.110.0x	0.13-0.1x	0.24+0.2x	0.00	N/A	N/A	0.000.0x	0.030.0x	0.06
FCF Margin	N/A	-12.8%-2.3pp	-10.5%+38.0pp	-48.5%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Margin	N/A	N/A	N/A	-193.0%	-634.9%	-190.1%	-21.7%+8.8pp	-30.5%
Net Margin	N/A	N/A	N/A	-206.3%	N/A	-199.9%	-43.5%-9.1pp	-34.3%
Return on Assets	N/A	-8.3%+91.0pp	-99.3%-30.2pp	-69.1%	N/A	-19.5%-15.2pp	-4.3%-0.7pp	-3.6%
Current Ratio	0.020.0x	0.060.0x	0.070.0x	0.080.0x	0.07-0.1x	0.17+0.1x	0.08-0.1x	0.13
FCF Margin	N/A	N/A	N/A	4.5%+2.9pp	1.6%+5.3pp	-3.7%+38.6pp	-42.3%-15.2pp	-27.1%

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

No annual filing on record for: FY2015, FY2016, FY2017, FY2018, FY2019.

Note: Shareholder equity is negative (-$1.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.02), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Cardiac Biotech Solutions Inc CBSC

$6.5M

Encision ECIA

$715K

Reflect Scientfc RSCF

$4.3M

Standard Dental Labs Inc TUTH

$3.1M

United Health Pr UEEC

$11.3M

Where Innovative Medtech Inc Ranks

Frequently Asked Questions

What are Innovative Medtech Inc's total assets?

Innovative Medtech Inc (IMTH) had $250K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Innovative Medtech Inc have outstanding?

Innovative Medtech Inc (IMTH) had 54M shares outstanding as of fiscal year 2025.

What is Innovative Medtech Inc's current ratio?

Innovative Medtech Inc (IMTH) had a current ratio of 0.02 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Why is Innovative Medtech Inc's debt-to-equity ratio negative or not reported?

Innovative Medtech Inc (IMTH) has negative shareholder equity of -$1.1M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.